The addition of the more specific and potent FLT3 inhibitor gilteritinib to azacitidine in older unfit patients with AML with mutated FLT3 (LACEWING trial) did not provide supportive evidence to improve OS [14]. The gene discussed is FLT3; the disease is acute myeloid leukemia.